IFM Therapeutics

With the business year almost complete, a review of biopharmaceutical dealmaking showed that Novartis, in particular, enjoyed a very productive year with 21 transactions overall, including six acquisi

Who: Novartis/IFM Therapeutics What: Novartis is exercising an option to buy IFM Due under a collaboration and option agreement between the big pharma company and the IFM Therapeutics subsidiary in

[Sidebar#SC145549] Biopharmaceutical companies and other life science start-ups may access $1.28bn in new venture capital available through four different sources, including Eir Venture Partners AB’s

Gary Glick’s fourth biotechnology firm, Scorpion Therapeutics , emerged from stealth mode on 26 October with $108m to develop small molecules that are safer, more tolerable and provide deeper, more d